Literature DB >> 3510578

Prognosis in chronic obstructive pulmonary disease.

N R Anthonisen, E C Wright, J E Hodgkin.   

Abstract

We recruited 985 patients with COPD but without hypoxemia or other serious disease, treated them in a standard fashion, and followed them closely for nearly 3 yr. At the time of recruitment the patients were carefully characterized as to symptom severity, lung function, exercise tolerance, and quality of life, and studies of lung function were repeated during follow-up. Overall mortality was 23% in 3 yr of follow-up. Patient age and the initial value of the FEV1 were the most accurate predictors of death; when FEV1 before bronchodilator was used, the response to bronchodilators was directly related to survival, but this relationship became nonsignificant when postbronchodilator FEV1 was used as a primary predictor. After adjustment for age and FEV1, mortality was related positively to TLC, resting heart rate, and perceived physical disability, and related negatively to exercise tolerance. These relationships, though significant, were relatively weak. When standardized for age and FEV1, mortality in the present series was less than that of a previous series (4), and the same as that of hypoxemic patients with COPD who received continuous home O2 therapy. Changes in FEV1 with time averaged -44 ml/yr, but the standard deviation was large. Patients with low initial values of FEV1 showed relatively little further decline, probably indicating a survivor effect. In patients with well-preserved initial FEV1, rate of decline correlated negatively with bronchodilator response, symptomatic wheezing, and psychological disturbances.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3510578     DOI: 10.1164/arrd.1986.133.1.14

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  89 in total

Review 1.  Lung transplantation for chronic obstructive pulmonary disease: an exercise in quality rather than quantity?

Authors:  P A Corris
Journal:  Thorax       Date:  1999-08       Impact factor: 9.139

Review 2.  Airway hyperresponsiveness and COPD mortality.

Authors:  J Vestbo; E F Hansen
Journal:  Thorax       Date:  2001-09       Impact factor: 9.139

Review 3.  How should COPD patients exercise during respiratory rehabilitation? Comparison of exercise modalities and intensities to treat skeletal muscle dysfunction.

Authors:  M A Puhan; H J Schünemann; M Frey; M Scharplatz; L M Bachmann
Journal:  Thorax       Date:  2005-05       Impact factor: 9.139

Review 4.  Chronic obstructive pulmonary disease.

Authors:  N R Anthonisen
Journal:  Can Respir J       Date:  2007-10       Impact factor: 2.409

Review 5.  Guideline-oriented perioperative management of patients with bronchial asthma and chronic obstructive pulmonary disease.

Authors:  Michiaki Yamakage; Sohshi Iwasaki; Akiyoshi Namiki
Journal:  J Anesth       Date:  2008-11-15       Impact factor: 2.078

6.  Low morphometric complexity of emphysematous lesions predicts survival in chronic obstructive pulmonary disease patients.

Authors:  Jeongeun Hwang; Yeon-Mok Oh; Minho Lee; Seunghyun Choi; Joon Beom Seo; Sang Min Lee; Namkug Kim
Journal:  Eur Radiol       Date:  2018-06-29       Impact factor: 5.315

Review 7.  Palliative care in chronic obstructive pulmonary disease: a review for clinicians.

Authors:  David A Seamark; Clare J Seamark; David M G Halpin
Journal:  J R Soc Med       Date:  2007-05       Impact factor: 5.344

Review 8.  Natural history of emphysema.

Authors:  Omar A Minai; Joshua Benditt; Fernando J Martinez
Journal:  Proc Am Thorac Soc       Date:  2008-05-01

9.  Heart rate variability and disease characteristics in patients with COPD.

Authors:  Carlos A Camillo; Fabio Pitta; Heloíse V Possani; Marcus V R A Barbosa; Divina S O Marques; Vinícius Cavalheri; Vanessa S Probst; Antonio F Brunetto
Journal:  Lung       Date:  2008-09-25       Impact factor: 2.584

10.  Reversible bronchial obstruction and disease-related health status in COPD.

Authors:  R A Incalzi; V Bellia; S Maggi; C Imperiale; O Capparella; R Pistelli; V Grassi
Journal:  Qual Life Res       Date:  2002-09       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.